AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
BioXcel Therapeutics, Inc.
Video analysis: BTAI
All videosNo video analysis for this stock yet. Request one from our team.
News: BTAI
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH (“Teva”), a subsidiary of Teva Pharmaceutical Industries Ltd.
Biopharma firm BioXcel Therapeutics files for bankruptcy in US
AI-driven biopharma firm BioXcel Therapeutics filed for Chapter 11 bankruptcy protection in the U.S. on Thursday.
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $2.45 per share a year ago.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Average Recommendation of “Hold” by Brokerages
Shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI - Get Free Report) have received an average recommendation of "Hold" from the four ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation
